Thyroid cancer is common endocrinological malignancy, accounting for approximately 1% of all new malignancies and its incidence is increasing 1,2 . Recognized risk factors for thyroid malignancy include young above 20 years or more than 70 years, male gender and history of irradiation exposure 3, 4 . Predictors of malignancy in thyroid nodules include the hard and fixed lesions on clinical examination, rapidly growing nodules, associated hoarseness, dysphagia or lymphadenopathy; however, most of these symptoms and signs are relatively uncommon at diagnosis 5, 6 . Moreover, thyroid gland harboring malignancy is clinically indistinguishable from those that do not. The most challenging issue to clinicians is to identify those minorities who have malignancy and who would require early surgical intervention 7 .
Thyroid cancer is common endocrinological malignancy, accounting for approximately 1% of all new malignancies and its incidence is increasing 1, 2 . Recognized risk factors for thyroid malignancy include young above 20 years or more than 70 years, male gender and history of irradiation exposure 3, 4 . Predictors of malignancy in thyroid nodules include the hard and fixed lesions on clinical examination, rapidly growing nodules, associated hoarseness, dysphagia or lymphadenopathy; however, most of these symptoms and signs are relatively uncommon at diagnosis 5, 6 . Moreover, thyroid gland harboring malignancy is clinically indistinguishable from those that do not. The most challenging issue to clinicians is to identify those minorities who have malignancy and who would require early surgical intervention 7 .
Fine needle aspiration biopsy (FNAB) is the gold standard and the most cost-effective method of determining the nature of a thyroid nodule 8 . Its diagnostic sensitivity and specificity ranges between 65%-100%, false-positive or false-negative results reported in about 5% 9, 10 . Its results are non-diagnostic or indeterminate in only 20%-25% of the cases. To increase its diagnostic efficacy, it could be combined with other investigations such as ultrasonography or other laboratory investigations.
Recently, controversial studies claimed that Thyrotropin (TSH) has a predictive value in papillary thyroid carcinoma (PTC) due to its central role in the regulation of thyroid function and gland growth; however, the issue still remains to be settled.
The aim of this study is to evaluate TSH level as a predictor of PTC among Bahraini patients harboring thyroid nodules.
METHOD
Three hundred nineteen patients who presented with thyroid nodules and attended the FNAC clinic or had surgical resection of thyroid nodule were included in the study from January 2009 to December 2013. Laboratory FNAB cytology, histopathology reports, biochemistry results and personal characteristics were documented.
Cases of medullary thyroid carcinoma, lymphoma, and anaplastic carcinoma were excluded because they are not TSH dependent; Hashimoto's thyroiditis and Hurtle cell change were considered as benign thyroid disease (BTD). Reports of malignant cells seen on cytology were labelled positive PTC and were confirmed histologically. False-negative cytology results were defined as one or more diagnostic aspirates without suspicious or malignant features, but histopathology revealed malignancy. Cases were considered to be true-negative if both cytological and histopathology diagnostic results confirm BTD.
Thyrotropin hormone (TSH) was measured using electrochemiluminescence immunoassay "ECLIA" (Roche Elyces analyzer, with a sensitivity of 0.005uIU/L). The reference range for TSH was 0.25-5uIU/L. Patients were divided into four groups according to their TSH levels.
Group 1 included patients with TSH level <0.25uIU/L, group 2 included patients with 0.26-2.2mIU/L, group 3 included patients with TSH levels between 2.3-5mIU/L, and group 4 included those with TSH level >5uIU/L. Sensitivity, specificity, and positive and negative predictive values of FNAB were calculated according to the final diagnostic outcome which was defined as the presence or absence of PTC. Other statistical analyses were performed using SPSS version 20. Serum TSH and age were considered as continuous variables.
RESULT
Three hundred nineteen patients with thyroid nodule were reviewed. Two hundred seventy-seven (86.8%) patients were females, 42 (13.2%) were males. The minimum age was 16 years and the maximum was 85 years. The mean age was 45.7 years (+13.3); the mean age of females was 45.1 (+12.8) compared to males 50.1 (+15.8) years.
Thirty-seven (11.6%) patients had PTC and 282 (88.4%) patients had benign multinodular goiter (BMNG). Twenty-eight (10.1%) female patients and 9 (21.4%) male patients had PTC, (P<0.05). The mean TSH for all patients was 5.85 mIU/L+20.6 meaning, the lowest value was 0.0 mIU/L and the highest value was 193 mIU/L. The mean TSH level was 5.8+20.6mIU/L for all patients. TSH mean level was 2.7 (+0.8) mIU/L for patients with BTD whereas it was 29.2 (+53.8) mIU/L in PTC patients. Mean TSH in the female group was 5.8 (+9.4) mIU/L versus 5.6 (+21.8) mIU/L in the male group, see table 1. Binary and stepwise logistic regression analysis revealed that TSH level is predictor of PTC even in association with age and gender, see table 3. However, binary logistic regression revealed that gender rather than age was predictor of PTC. In different patients' subgroups, the same finding is predicted in the high sector of the clinical reference range. Above the clinical reference range, TSH was predictor of PTC either alone or in association with gender. However, gender and age separately were not predictors of PTC, see table 4. 
DISCUSSION
Comparison between cytopathology and final histopathology diagnosis revealed true-negative cytological diagnosis of PTC in 283 (88.7%) patients; 27 (8.4%) patients were diagnosed as true positive cytological category. Only 2 (0.6%) of patients who had false-positive result were cytologically diagnosed as malignant. Seven (2.1%) false-negative cytological diagnoses were made. Our FNAB result revealed sensitivity of 79.4%, specificity of 99.3%, positive predictive value of 93.1% and negative predictive value of 97.59%, which were comparable with other studies 9 .
TSH in thyroid malignancy is still a matter of controversy. Some studies disagree with its role in initiating and/or promoting the growth of preexisting thyroid cancers. Other studies emphasized the role of other growth factors such as insulin like growth factor-I (IGF-I) as a more potent stimulator of thyroid cancer growth 11, 12 . Other studies stated that TSH requires cooperation with insulin/IGF-1 to exert its proliferative effects 13 . In addition, other studies concluded that thyroid cancer is known to occur in thyroid nodule in a thyroid lobe in which activity is suppressed by the hyper-functioning nodules in the other lobe 14 . Other researchers studied TSH receptors signal transduction and found that TSH receptor mutations in regions functionally associated with increased signal transduction do not commonly occur in thyroid carcinomas 15 .
In our study, TSH >5.0 mIU/L, remained as an independent predictor either on its own or in association with gender but not with age, which is similar to other studies 16 . Statistical analysis revealed that female gender was at a higher risk of possessing PTC in the overall patient's groups or in subgroups. The highest estimated risk of PTC was at TSH level between 2.3-5 mIU/L, where females had an estimated risk 5 times more than males. Other studies have reported similar findings [17] [18] [19] [20] .
Boelaert et al found serum TSH concentration as an independent predictor of the presence of thyroid malignancy in addition to patients' age and gender 18 . They confirmed that the lowest risk of malignancy was in patients with subclinical hyperthyroidism (TSH<0.4 mIU/l), and the prevalence of thyroid cancer was high in those with subclinical hypothyroidism (TSH>5.5 mIU/l).
Haymart et al found that the likelihood of malignancy was 16% if TSH was <0.06 mIU/L, 25% if TSH 0.40-1.39 mIU/L, 35% if TSH 1.40-4.99 mIU/L and 52% if TSH 5.0 mIU/l or greater 21 . A study of 50 patients undergoing thyroidectomy has confirmed increased risk of cancer diagnosis in subjects with serum TSH concentrations in the upper three quartiles of TSH values compared with patients whose serum TSH was in the lower quartile 22 .
TSH as a predictor of PTC could have several clinical implications. Serum TSH in patients with thyroid nodules may help in diagnosis combined with clinical, radiological, and cytological criteria. Clinicians would be more inclined to perform fine-needle aspiration of nodules in patients with higher serum TSH. Furthermore, thyroid cancer screening could be considered in patients with TSH elevations. Finally, if serum TSH plays a significant role as a causative factor for thyroid cancer, a potentially great benefit would be gained from TSH suppression therapy 22 . It is important to recognize that a suppressed TSH does not rule out a diagnosis of thyroid cancer. In this group, the recent genome-wide association study has indicated that serum TSH concentrations are lower in patients carrying one of two alleles who are at increased risk of PTC 23 . It is prudent to realize that serum TSH alone must not be used for diagnostic decision.
CONCLUSION
High incidence of PTC is associated with TSH above the clinical reference range. It is recommended that patients with TSH in the upper reference range should be subjected to FNAB for possible carcinoma.
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